E
Alain Moussy

A leap of faith – AB Science and masitinib in pancreatic cancer

Interview with Alain Moussy, CEO of AB Science, an emerging French biotechnology company.

October 26, 2009
E
Susan Desmond Hellmann

The future of Oncology

Interview with Dr. Susan Desmond-Hellmann, formerly Head of R&D at Genentech and now Chancellor at UCSF.

March 17, 2010
E
camidge

Crizotinib and ALK rearrangements in lung cancer: an interview with Dr Ross Camidge

An interview with Dr Ross Camidge about crizotinib (Xalkori) and ALK rearrangements in lung cancer

November 30, 2010
E
Dr Charles Sawyers Lasker Video

Making a difference to the lives of cancer patients: An interview with Dr Charles Sawyers

Interview with Charles L. Sawyers, MD is Chair of the Human Oncology and Pathogenesis Program at the Memorial Sloan-Kettering Cancer Center (MSKCC), and an Investigator with the Howard Hughes Medical Institute.

May 3, 2011
E
Dr Gordon Mills Interview Stockholm

Making a Difference: an interview with Dr Gordon Mills

Video interview at EMCC 2011 in Stockholm with Dr Gordon B. MIlls, chairman of the Department of Systems Biology, Chief of the Section of Molecular Therapeutics, Professor of Medicine and Immunology, and Anne Rife Cox Chair in Gynecology at the MD Anderson Cancer Center.

October 4, 2011
E
Dr Ray DuBois

New research demonstrates the link between inflammation and early development of colon cancer

Interview with Dr Ray DuBois, Provost & Executive Vice President, The University of Texas MD Anderson Cancer Center, on the potential role of inflammation and silencing of tumour suppressor genes in early colorectal cancer.

January 23, 2012
E
David Hung website portrait

Update on Medivation’s MDV3100 in advanced prostate cancer

Interview with Dr David Hung, CEO of Medivation

January 31, 2012
E
re 4.4.0">

Raised platelets reduce survival in ovarian cancer

Interview with Dr. Anil K. Sood who is Professor and Director of the Blanton-Davis Ovarian Cancer Research Program in the Departments of Gynecologic Oncology and Cancer Biology at the M. D. Anderson Cancer Center.

February 15, 2012
E
Dr Razelle Kurzrock

Cancer Clinical Trials: Companion Diagnostics or Gene Sequencing?

Interview with Dr Razelle Kurzrock, who heads up the Department of Investigational Cancer Therapeutics group at the MD Anderson Cancer Center.

February 21, 2012
E
dr-shore-150x150

Update on advanced prostate cancer including enzalutamide (MDV3100) and abiraterone

Interview with Dr Neal Shore, one of the AFFIRM trialists about his perspective of the impact of enzalutamide on his patients.

May 25, 2012
E
Dr Hedy Lee Kindler Copryight The University of Chicago

Making a difference in pancreatic cancer – an interview with Dr Hedy Lee Kindler

Interview with Dr Hedy Lee Kindler on new developments in advanced pancreatic cancer at ASCO GI

February 12, 2013
E
Professor Bertrand Tombal

Making a difference in Advanced Prostate Cancer – an interview with Bertrand Tombal

Interview with Prof Bertrand Tombal on enzalutamide in advanced hormone sensitive prostate cancer at ASCO GU

February 15, 2013
E
ASCO 2013 Dr Susan O'Brien

Exciting times in CLL: an ASCO 2013 interview with Dr Susan O’Brien

Video interview at ASCO 2013 with Dr Susan O'Brien, Ashbel Smith Professor in the Department of Leukemia at the University of Texas, MD Anderson Cancer Center in Houston, in which she discusses many of the exciting new targeted therapies that are set to change the treatment of chronic lymphocytic leukemia (CLL).

June 10, 2013
E
Source: Gilead

Making a difference in NHL and CLL: an interview with Dr Carol Gallagher

Dr Carol Gallagher is the former CEO of Calistoga before it was acquired by Gilead. CAL-101, a PI3K-delta inhibitor is now known as idelalisib and in phase 3 development for CLL and indolent NHL. This is a great example of a successful R&D strategy for a targeted therapy that is making a difference to patients lives.

January 10, 2014